Cover Image
市場調查報告書

高血糖症:開發平台分析

Hyperglycemia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 253660
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
高血糖症:開發平台分析 Hyperglycemia - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 30 Pages
簡介

高血糖症是血糖值異常高時產生的症狀。原因有食物和運動的選擇、疾病、非糖尿病治療藥,或是未攝取充分的降血糖藥等。症狀有頻尿、視力障礙、疲勞性頭痛、噁心·嘔吐、嘴唇乾、昏睡、混亂狀態等。治療方法有抗高血糖治療及胰島素治療。

本報告提供全球各國的高血糖症(過血糖症)治療方法的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查。

簡介

高血糖症概要

治療藥的開發

  • 高血糖症開發中產品的概要
  • 高血糖症開發中產品比較分析

各企業正在開發的高血糖症治療藥

大學/研究機關研究中的高血糖症治療藥

開發中產品的概要

  • 臨床實驗階段有的產品
  • 初期階段有的產品

高血糖症治療藥:開發中的產品一覽(各企業)

高血糖症治療藥:研究中的產品一覽(各大學/研究機關)

高血糖症開發治療藥的企業

  • Kissei藥品工業
  • 田邊三菱製藥
  • PhaseBio Pharmaceuticals, Inc.

高血糖症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 投藥各途徑
  • 各投藥法
  • 各分子類型

藥物簡介

高血糖症治療藥:最新的開發中產品

高血糖症治療藥:開發暫停的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9458IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperglycemia - Pipeline Review, H1 2017, provides an overview of the Hyperglycemia (Metabolic Disorders) pipeline landscape.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. Symptoms include frequent urination, blurred vision, fatigue headache, nausea and vomiting, dry mouth, coma and confusion. Treatment includes anti-hyperglycemic therapy and insulin therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperglycemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Hyperglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperglycemia (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperglycemia - Overview
    • Hyperglycemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hyperglycemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hyperglycemia - Companies Involved in Therapeutics Development
    • Mitsubishi Tanabe Pharma Corp
  • Hyperglycemia - Drug Profiles
    • Drugs to Inhibit ABHD6 for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FGH-10019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KR-62980 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize Glucagon Receptor for Hyperglycemia and Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hyperglycemia - Dormant Projects
  • Hyperglycemia - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hyperglycemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hyperglycemia - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Hyperglycemia - Dormant Projects, H1 2017
  • Hyperglycemia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Hyperglycemia, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top